Phages Provide Safety Net In Post-Antibiotic Era

February 13, 2020

News

Comments Off on Phages Provide Safety Net In Post-Antibiotic Era

February 13, 2020 | To fully appreciate the potential of Adaptive Phage Therapeutics (APT), it’s helpful to review history through the lens of company co-founder and Chief Scientific Officer Carl Merril. For nearly five decades, Carl has been championing the idea of using bacteriophages to treat infectious diseases—an idea for which he has been variably applauded, questioned, ignored, scolded, and, ultimately, vindicated.

Adaptive Phage Therapeutics on NPR

February 11, 2020

News

Comments Off on Adaptive Phage Therapeutics on NPR

Bacteriophage: A Force Of Nature As bacteria evolve to become more resistant to antibiotics, dangerous infections are taking their toll on human lives. We hear from John Haverty who, after knee replacement surgery generated an unrelenting infection … found himself facing amputation of his leg. Enter a new treatment called ‘phage therapy’ and Greg Merril, […]

Adaptive Phage Therapeutics Selected for Startup Grind’s Global 2020 Accelerate Program

February 11, 2020

News

Comments Off on Adaptive Phage Therapeutics Selected for Startup Grind’s Global 2020 Accelerate Program

Company is Recognized Top 1% among 4,000 applicants from 133 Countries GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced that the company has been selected to participate in the Accelerate Program at the Startup […]

Adaptive Phage Therapeutics Selected for Startup Grind’s Global 2020 Accelerate Program

February 10, 2020

Press Releases

Comments Off on Adaptive Phage Therapeutics Selected for Startup Grind’s Global 2020 Accelerate Program

–Company is Recognized Top 1% among 4,000 applicants from 133 Countries– February 10, 2020 10:00 AM Eastern Standard Time GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced that the company has been selected to participate […]

Adaptive Phage Therapeutics Awarded Initial Contract with Department of Defense

January 9, 2020

News

Comments Off on Adaptive Phage Therapeutics Awarded Initial Contract with Department of Defense

Funds Designated to Support Clinical Development of PhageBankTM Precision Bacteriophage Therapeutic GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced the Department of Defense (DoD) has awarded APT a contract of $10.2 million for the […]

Adaptive Phage Therapeutics Awarded Initial Contract with Department of Defense

January 8, 2020

Press Releases

Comments Off on Adaptive Phage Therapeutics Awarded Initial Contract with Department of Defense

Funds Designated to Support Clinical Development of PhageBankTM Precision Bacteriophage Therapeutic January 08, 2020 10:00 AM Eastern Standard Time GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced the Department of Defense (DoD) has awarded APT a contract of […]

Hackensack Meridian Health Invests in Adaptive Phage Therapeutics, Aiming to Kill ‘Superbugs’ as Part of Bear’s Den Innovation Program

December 4, 2019

News

Comments Off on Hackensack Meridian Health Invests in Adaptive Phage Therapeutics, Aiming to Kill ‘Superbugs’ as Part of Bear’s Den Innovation Program

EDISON, N.J., Dec. 4, 2019 /PRNewswire/ — Hackensack Meridian Health has invested in the clinical-stage biotechnology company  Adaptive Phage Therapeutics (APT), as part of the health network’s successful innovation program, the Bear’s Den. APT is taking aim at the toughest multi-drug resistant “superbugs” using precision-targeted, genomically-screened, and highly purified viruses known as bacteriophages, or “phages.”

APT CEO Greg Merril discusses phage therapy on NASDAQ #TradeTalks

November 6, 2019

News

Comments Off on APT CEO Greg Merril discusses phage therapy on NASDAQ #TradeTalks

Greg Merril discusses phage therapy on NASDAQ #TradeTalks with Jill Malandrino

Phage Therapy Could Beat Drug-Resistant Illnesses

November 1, 2019

News

Comments Off on Phage Therapy Could Beat Drug-Resistant Illnesses

Is phage therapy here to stay? Scientific American discusses phage therapy.

Adaptive Phage Therapeutics to Present to Investors at 2019 World Antimicrobial Resistance Congress

October 30, 2019

News

Comments Off on Adaptive Phage Therapeutics to Present to Investors at 2019 World Antimicrobial Resistance Congress

GAITHERSBURG, Md.–(BUSINESS WIRE)– –CEO to Outline Vision at Global Gathering of Infectious Disease Leaders and Investors– Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced that Greg Merril, CEO and co-founder of APT, will present an overview […]